Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East – 2021 update

Nasreen Al Sayed ◽  
Wael Almahmeed ◽  
Fahad Alnouri ◽  
Khalid Al Waili ◽  
Hani Sabbour ◽  
2016 ◽  
Vol 225 ◽  
pp. 268-283 ◽  
Nasreen Al Sayed ◽  
Khalid Al Waili ◽  
Fatheya Alawadi ◽  
Saeed Al-Ghamdi ◽  
Wael Al Mahmeed ◽  

2016 ◽  
Vol 15 (1) ◽  
Nguyen Thi Hong Hanh ◽  
Bui Thi Nhung ◽  
Duong Thi Anh Dao ◽  
Le Thi Tuyet ◽  
Le Thi Hop ◽  

2021 ◽  
Vol 20 (1) ◽  
Zhen-Vin Lee ◽  
Elmer Jasper Llanes ◽  
Renan Sukmawan ◽  
Nuntakorn Thongtang ◽  

AbstractCardiovascular disease (CVD) is a major cause of mortality and morbidity within the Asia-Pacific region, with the prevalence of CVD risk factors such as plasma lipid disorders increasing in many Asian countries. As members of the Cardiovascular RISk Prevention (CRISP) in Asia network, the authors have focused on plasma lipid disorders in the six countries within which they have clinical experience: Indonesia, Malaysia, Philippines, Thailand, Vietnam, and Australia. Based on country-specific national surveys, the prevalence of abnormal levels of total cholesterol, low- and high-density lipoprotein cholesterol (LDL-C and HDL-C, respectively), and triglycerides (TG) are reported. An important caveat is that countries have used different thresholds to define plasma lipid disorders, making direct comparisons difficult. The prevalence of abnormal lipid levels was as follows: high total cholesterol (30.2–47.7%, thresholds: 190–213 mg/dL); high LDL-C (33.2–47.5%; thresholds: 130–135 mg/dL); low/abnormal HDL-C (22.9–72.0%; thresholds: 39–50 mg/dL); and high/abnormal TG (13.9–38.7%; thresholds: 150–177 mg/dL). Similarities and differences between country-specific guidelines for the management of plasma lipid disorders are highlighted. Based on the authors’ clinical experience, some of the possible reasons for suboptimal management of plasma lipid disorders in each country are described. Issues common to several countries include physician reluctance to prescribe high-dose and/or high-intensity statins and poor understanding of disease, treatments, and side effects among patients. Treatment costs and geographical constraints have also hampered disease management in Indonesia and the Philippines. Understanding the factors governing the prevalence of plasma lipid disorders helps enhance strategies to reduce the burden of CVD in the Asia-Pacific region.

1989 ◽  
Vol 8 (sup1) ◽  
pp. 33S-45S ◽  
Simeon Margolis ◽  
Adrian S. Dobs

2015 ◽  
Vol 61 (1) ◽  
pp. 7-18 ◽  
P.G. Lokhov ◽  
D.L. Maslov ◽  
E.E. Balashova ◽  
O.P. Trifonova ◽  
N.V. Medvedeva ◽  

A new method for the analysis of blood lipid based on direct mass spectrometry of lipophilic low molecular weight fraction of blood plasma has been considered. Such technique allows quantification of hundreds of various types of lipids and this changes existing concepts on diagnostics of lipid disorders and related diseases. The versatility and quickness of the method significantly simplify its wide use. This method is applicable for diagnostics of atherosclerosis, diabetes, cancer and other diseases. Detalization of plasma lipid composition at the molecular level by means of mass spectrometry allows to assess the effectiveness of therapy and to optimize the drug treatment of cardiovascular diseases by phospholipid preparations.

Sign in / Sign up

Export Citation Format

Share Document